



ASX / MEDIA RELEASE

13th January 2017

Investigation of Concerns around CEO Share Trading & Action Taken by the Board

Sydney, Australia: 13th January 2017 – Sirtex Medical Limited (ASX:SRX) previously announced on 16th December 2016 that the Board of Directors had engaged the company’s legal advisers, Watson Mangioni, to coordinate an investigation into the trading of shares in Sirtex in October 2016 by the Chief Executive Officer, Mr Gilman Wong. The announcement noted that the results of that investigation were expected to be available in January 2017.

That investigation has now been completed, and a report from Watson Mangioni has been provided to, and considered by, the Board. The contents of that report are privileged and confidential.

After due consideration, the Board of Sirtex has today terminated Mr Wong’s employment with Sirtex, with immediate effect. Mr Wong’s salary and statutory entitlements will be paid to the date of termination. All unvested performance rights previously issued to Mr Wong have been forfeited.

Mr Nigel Lange has been appointed as Acting CEO, effectively immediately. Mr Lange is the current Chief Operating Officer of Sirtex, with over 14 years direct experience in the core SIR-Spheres[®] Y-90 resin microspheres business.

Mr Lange commented “I look forward to delivering on our strategies, to maximise the potential of our SIR-Spheres microspheres technology, and to reinstate value to our shareholders.”

Sirtex will be conducting a thorough executive search and recruitment process to fill the position of CEO and intends to appoint an executive search firm to oversee this process and conduct a global search.

Separately, Sirtex is pleased to announce the appointment of Anthony (Tony) Dixon as the incoming Chief Executive Officer, EMEA with immediate effect.

Mr Lange noted that “Tony has been with Sirtex Medical Europe for nine years and has a strong track record in oncology and the medical devices sector, having served as National Sales Manager UK, Director of Marketing and more recently the Vice President of Marketing EMEA.”

He also stated that he expects the appointment of a Chief Executive Officer, APAC will be made prior to the end of January.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

About Sirtex Medical

Sirtex Medical Limited (ASX: SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at more than 1,000 medical centres in over 40 countries. For more information, please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Darren Smith
CFO & Company Secretary
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd